Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KDM5A | P29375 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.38 |
| ▸ | ENPP3 | O14638 | 2/20 | 0.38 |
| ▸ | ALPL | P05186 | 2/20 | 0.38 |
| ▸ | XIAP | P98170 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30864281 | 0.88 | LMNA (0.40) | LMNAGAAGFERSMN1; SMN2ALDH1A1 | |
| SCHEMBL25416955 | 0.84 | LMNA (0.58) | LMNASMN1; SMN2ALDH1A1KMT2AENPP3 | |
| SCHEMBL23355414 | 0.81 | RAB9A (0.50) | LMNAGAAALDH1A1TDP1MEN1 | |
| SCHEMBL9959424 | 0.75 | CA12 (0.34) | LMNAGAASMN1; SMN2ALDH1A1TDP1 | |
| SCHEMBL3076452 | 0.75 | KDM5A (0.41) | LMNAGAAGFERSMN1; SMN2ALDH1A1 | |
| SCHEMBL9959674 | 0.73 | TDP1 (0.38) | LMNAALDH1A1TDP1KDM5AKDM4C | |
| SCHEMBL17145452 | 0.73 | GAA (0.43) | LMNAGAAALDH1A1TDP1MEN1 | |
| SCHEMBL5066688 | 0.72 | LMNA (0.74) | LMNASMN1; SMN2ALDH1A1KDM5AKDM4C | |
| SCHEMBL20602282 | 0.72 | AHR (0.40) | LMNAGAASMN1; SMN2ALDH1A1NPC1 | |
| SCHEMBL24633616 | 0.71 | MAP4K4 (0.44) | LMNAMEN1KMT2ARAB9ATP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250243197-A1 | Anthelmintic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-07-31 | — | — | US | disclosed |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES | 2025-05-01 | — | — | US | disclosed |
| US-12269822-B2 | Anthelminthic heterocyclic compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2025-04-08 | — | — | US | disclosed |
| CN-112996788-B | Anthelmintic heterocyclic compounds | 勃林格殷格翰动物保健美国公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117858877-A | C-linked inhibitors of ENL/AF9 YEATS | 桥梁药品有限公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4337662-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | Bridge Medicines (US) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022240830-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | BRIDGE MEDICINES (US) | 2022-11-17 | — | — | WO | disclosed |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2022-02-17 | — | — | US | disclosed |
| CN-112996788-A | Anthelmintic heterocyclic compounds | 勃林格殷格翰动物保健美国公司 | 2021-06-18 | — | — | CN | disclosed |
| EP-3820870-A1 | ANTHELMINTHIC HETEROCYCLIC COMPOUNDS | Boehringer Ingelheim Animal Health USA Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| US-5691347-A | ANGIOTENSIN II INHIBITORS AND VASOCONSTRICTION | ROUSSEL UCLAF (FR) | 1997-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048903-A1 | Anthelminthic Heterocyclic Compounds | SDHA, PAH, PIGS | LMNA 2182/4885GAA 524/4885GFER 2027/4885 |
| US-12269822-B2 | Anthelminthic heterocyclic compounds | SDHA, PAH, PIGS | LMNA 2182/4885GAA 524/4885GFER 2027/4885 |
| US-20250243197-A1 | Anthelmintic Heterocyclic Compounds | PAH, PIGS, SDHA | LMNA 1937/4885GAA 706/4885GFER 1933/4885 |
| US-20250136592-A1 | C-LINKED INHIBITORS OF ENL/AF9 YEATS | MLLT3, MLLT1, YEATS2 | LMNA 597/4885GAA 2786/4885GFER 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.